# Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)

> **NCT01803321** · PHASE1 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 24 (actual)

## Conditions studied

- Systemic Juvenile Idiopathic Arthritis

## Interventions

- **DRUG:** rilonacept (IL-1 Trap)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01803321
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2013-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01803321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01803321, "Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01803321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*